

REGENERON PHARMACEUTICALS INC

Form 8-K

December 16, 2005

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **December 16, 2005 (December 12, 2005)**

**REGENERON PHARMACEUTICALS, INC.**

---

(Exact name of registrant as specified in its charter)

**New York**

---

**0-19034**

---

**No. 13-3444607**

---

(State or other jurisdiction of  
incorporation)

(Commission  
File Number)

(IRS Employer  
Identification No.)

**777 Old Saw Mill River Road, Tarrytown, New  
York**

---

**10591-6707**

---

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code (914) 347-7000

**NOT APPLICABLE**

---

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 1.01 Entry into a Material Definitive Agreement

Item 9.01 Financial Statements and Exhibits

Exhibit Index

EX-10.01: FORM OF OPTION AGREEMENT

EX-10.02: FORM OF OPTION AGREEMENT

---

**Table of Contents****Item 1.01 Entry into a Material Definitive Agreement**

On December 12, 2005, the Compensation Committee of the Registrant's Board of Directors (the Committee) approved new option agreements to be used for the grant of non-qualified stock option awards to purchase shares of the Registrant's common, stock, par value \$0.001 per share, under the Registrant's 2000 Long-Term Incentive Plan.

The form of option agreement and related notice of grant approved by the Committee for use in connection with the grant of non-qualified stock options to the Registrant's named executive officers (as such term is defined in Item 402(a)(3) of Regulation S-K under the Securities and Exchange Act of 1933, as amended), chairman, and non-employee directors is attached hereto as Exhibit 10.01 and incorporated herein by reference. The form of option agreement and related notice of grant approved by the Committee for use in connection with the grant of non-qualified stock options to the Registrant's executive officers, other than the named executive officers, is attached hereto as Exhibit 10.02 and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits**

(c) *Exhibits.*

<b>Exhibit Number</b>	<b>Description</b>
10.01	Form of option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's non-employee directors and named executive officers.
10.02	Form of option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's executive officers other than the named executive officers.

**Table of Contents**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REGENERON PHARMACEUTICALS, INC.

Dated: December 16, 2005

By: /s/ Stuart Kolinski  
\_\_\_\_\_

Stuart Kolinski  
Vice President & General Counsel

**Table of Contents**

**Exhibit Index**

<b>Number</b>	<b>Description</b>
10.01	Form of option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's non-employee directors and named executive officers.
10.02	Form of option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's executive officers other than the named executive officers.